Epilepsy, impaired functioning, and quality of life in patients with tuberous sclerosis complex-Reference-Cited by-同舟云学术

Epilepsy, impaired functioning, and quality of life in patients with tuberous sclerosis complex

Published:2019-10-27 Issue:4 Volume:4 Page:581-592
ISSN:2470-9239
Container-title:Epilepsia Open
language:en
Short-container-title:Epilepsia Open

Author:

Vergeer Menno¹,Ranitz‐Greven Wendela L.¹,Neary Maureen P.²,Ionescu‐Ittu Raluca³,Emond Bruno³^ORCID,Sheng Duh Mei⁴,Jansen Floor¹,Zonnenberg Bernard A.¹

Affiliation:

1. University Medical Center Utrecht Utrecht Netherlands

2. Novartis Pharmaceuticals Corporation East Hanover NJ USA

3. Analysis Group, Inc. Montréal Québec Canada

4. Analysis Group, Inc. Boston MA USA

Funder

Novartis Pharmaceuticals Corporation

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/epi4.12365

Reference50 articles.

1. TS Association.Tuberous Sclerosis Association 2010. Available from URLhttp://www.tuberous-sclerosis.org/.Accessed August 15 2018.

2. The pathogenesis and imaging of the tuberous sclerosis complex

3. Urological Counseling and Followup in Pediatric Tuberous Sclerosis Complex

4. An epidemiological study of renal pathology in tuberous sclerosis complex

5. PSU33 Characteristics and Burden of Tuberous Sclerosis Complex: Results of a Patient and Caregiver Survey in the United States

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Cost-Utility Analysis of Add-On Cannabidiol Versus Usual Care Alone for the Treatment of Seizures Associated with Tuberous Sclerosis Complex in England and Wales;PharmacoEconomics - Open;2024-03-05

2. A single-center observational study on long-term neurodevelopmental outcomes in children with tuberous sclerosis complex;Orphanet Journal of Rare Diseases;2023-11-09

3. Understanding the impact of tuberous sclerosis complex: development and validation of the TSC-PROM;BMC Medicine;2023-08-08

4. Economic analysis of cerliponase alfa for treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2);Expert Review of Pharmacoeconomics & Outcomes Research;2023-04-03

5. Patient profile, management, and quality of life associated with Dravet syndrome: a cross-sectional, multicentre study of 80 patients in Spain;Scientific Reports;2023-02-27